MYOV - Myovant Sciences names industry veteran as commercial chief
Myovant Sciences (MYOV) appointed Lauren Merendino as Chief Commercial Officer, effective today; she has 20+ years of pharmaceutical and biotech leadership experience.Most recently, she served as VP, Neurological Rare Diseases at Genentech."The recent FDA approval in advanced prostate cancer and our upcoming regulatory milestones in uterine fibroids and endometriosis set us up for an exciting path forward. Lauren's experience of building and leading top-performing commercial teams will be critical in enabling our therapies to reach patients who can benefit the most," CEO David Marek commented.
For further details see:
Myovant Sciences names industry veteran as commercial chief